

PCT 2005

Docket No.: 09859/0202256-US0
(PATENT)



Express Mail Label No.

Dated: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Daisuke Machii et al.

Application No.: 10/519,630

Confirmation No.: N/A

Filed: December 23, 2004

Art Unit: N/A

For: **HETEROBICYCLIC COMPOUNDS**

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A summary/abstract translation of the non-English language documents is enclosed.

A copy of each document on the PTO/SB/08 is attached.

Citation No. BA is not in the English language. In accordance with 1.98(c), Applicants state:

The requirement for concise explanation of relevance of Citation No. BA is satisfied by the attached translation of the abstract (see MPEP § 609 A(3)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: March 28, 2005

Respectfully submitted,

By Chris T. Mizumoto (53,970) FLYNN BARRISON

Chris T Mizumoto

Registration No.: 42,899

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,630
				Filing Date	December 23, 2004
				First Named Inventor	Daisuke Machii
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09859/0202256-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	JP-03-204880-A	09-06-1991	Kyowa Hakko Kogyo Co. Ltd.	Abstract Only	✓
	BB	EP-0 884 318-A1	12-16-1998	Kyowa Hakko Kogyo Co., Ltd.		
	BC	EP-1 251 130-A1	10-23-2002	Kyowa Hakko Kogyo Co., Ltd.		
	BD	EP-1 092 435-A1	04-18-2001	Kyowa Hakko Kogyo Co., Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Patent Abstracts of Japan for 03-204880 published on September 6, 1991	
	CB	Adenosine A1 Antagonists. 3. Structure-Activity Relationships on Amelioration against Scopolamine- or N6-((R)-Phenylisopropyl) adenosine-Induces Cognitive Disturbance by Fumio SUZUKI et al, published in Journal of Medicinal Chemistry, Vo. 36, 1993, p. 2508-2518	
	CC	7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: A Potent and Water-Soluble Adenosine A1 Antagonist by Fumio SUZUKI et al, published in Journal of Medicinal Chemistry, Vol. 35, 1992, p. 3578-3581	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

W:1098 5910202		Date Considered	
-------------------	--	--------------------	--

